BRTX: financial statements from SEC — TradeAlmanac

BRTX

BioRestorative Therapies, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	23,170	11,800	303,300	25,000	233,600	89,100
Cost of revenue	7,385	10,570	8,729	2,909	18,243	6,490
Gross profit	15,785	1,230	294,571	22,091	215,357	82,610
Research and development	2m	3m	2m	2m	1m	1m
Selling, general and administrative	1m	1m	1m	3m	1m	1m
Operating expenses	3m	4m	4m	5m	3m	3m
Operating income	−3m	−4m	−3m	−5m	−2m	−2m
Net income	−2m	−3m	−3m	−5m	−1m	−4m
Earnings per share	−0.12	−0.33	−0.30	−0.64	−0.13	−0.50
Earnings per share, diluted	−0.12	−0.33	−0.30	−0.64	−0.13	−0.50
Weighted average shares	18m	9m	9m	8m	8m	8m
Weighted average shares, diluted	18m	9m	9m	8m	8m	8m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	3m	2m	602,444	2m	1m	547,890	1m	2m
Short-term investments	479,351	1m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−4m	−3m
Depreciation and amortisation	52,394	51,781
Share-based compensation	290,215	2m
Capital expenditure	—	36,400
Investing cash flow	968,447	2m
Financing cash flow	4m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)